In the clinical investigation of VEGF in ischemic patients for vascular angiogenesis, administration of recombinant human (rh) VEGF protein is required at multiple time points during the experiment, and only the high dosage group (1 mg per 50 kg body weight as an initial injection dose) showed improvement in angina [78]. This evidence concerns the gene VEGFA and angina pectoris.